CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype

Blood

Volumn 121, Issue 17, 2013, Pages 3469-3472

  Masetti, Riccardo ^a   Pigazzi, Martina ^b   Togni, Marco ^a   Astolfi, Annalisa ^a   Indio, Valentina ^a   Manara, Elena ^b   Casadio, Rita ^a   Pession, Andrea ^a   Basso, Giuseppe ^b   Locatelli, Franco ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; CBFA2T3 GLIS2 FUSION PROTEIN, HUMAN; CBFA2T3-GLIS2 FUSION PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; TUMOR MARKER;

ACUTE MYELOID LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CHILD; CHROMOSOME 16; CHROMOSOME INVERSION; CLINICAL ARTICLE; CYTOGENETICS; EVENT FREE SURVIVAL; FEMALE; FUSION GENE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MALE; PRIORITY JOURNAL; ACUTE GRANULOCYTIC LEUKEMIA; CLASSIFICATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; INFANT; MORTALITY; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84879397326     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-469825     Document Type: Article

References (21)

1. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5): 551-565.
2. Ho PA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group. Blood. 2009;113(26):6558-6566.
3. Cazzaniga G, Dell’Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005;106(4):1419-1422.
4. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97(1):89-94.
5. Staffas A, Kanduri M, Hovland R, et al; Nordic Society of Pediatric Hematology and Oncology (NOPHO). Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118(22):5905-5913.
6. Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br J Haematol. 2012;159(3):259-276.
7. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11): 1058-1066.
8. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
9. Andersson AK, Miller DW, Lynch JA, et al. IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia. 2011;25(10):1570-1577.
10. Pigazzi M, Ferrari G, Masetti R, et al. Low prevalence of IDH1 gene mutation in childhood AML in Italy. Leukemia. 2011;25(1):173-174.
11. Paganin M, Pigazzi M, Bresolin S, et al. DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study. Haematologica. 2011;96(12): 1886-1887.
12. Gruber TA, Larson Gedman A, Zhang J, et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012;22(5):683-697.
13. Thiollier C, Lopez CK, Gerby B, et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med. 2012;209(11):2017-2031.
14. Pession A, Rizzari C, Putti MC, et al. Results of the AIEOP AML 2002/01 study for treatment of children with acute myeloid leukemia [abstract]. Blood. 2009;114.Abstract 17. [ASH Annual Meeting Abstracts]
15. Shaffer LG, Tommerup N, eds. ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 2005.
16. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105-1111.
17. McPherson A, Hormozdiari F, Zayed A, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLOS Comput Biol. 2011; 7(5):e1001138.
18. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics. 2011;27(20):2903-2904.
19. Berger R, Le Coniat M, Romana SP, et al. Secondary acute myeloblastic leukemia with t(16;21) (q24;q22). involving the AML1 gene. Hematol Cell Ther. 1996;38(2): 183-186.
20. Gamou T, Kitamura E, Hosoda F, et al. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood. 1998;91(11): 4028-4037.
21. Li B, Rauhauser AA, Dai J, et al. Increased hedgehog signaling in postnatal kidney results in aberrant activation of nephron developmental programs. Hum Mol Genet. 2011;20(21): 4155-4166.